CEBPα mutation is an independent prognostic marker for OS irrespective of age, MLL-PTD, and FLT3-ITD status [43] and is another marker that permits the division of NC-AML into distinct clinical groups [25]. Here, CEBPA is linked to acute myeloid leukemia.